Modelling the epidemiological impact of intermittent preventive treatment against malaria in infants

PLoS ONE

Volumn 3, Issue 7, 2008, Pages

  Ross, Amanda ^a   Penny, Melissa ^a   Maire, Nicolas ^a   Studer, Alain ^a   Carneiro, Ilona ^b   Schellenberg, David ^b   Greenwood, Brian ^b   Tanner, Marcel ^a   Smith, Thomas ^a  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ARTESUNATE; CHLOROQUINE; FANSIDAR; IRON; PLACEBO; ANTIMALARIAL AGENT; PYRIMETHAMINE; SULFADOXINE; SULFADOXINE-PYRIMETHAMINE;

ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; FEVER; HEALTH CARE DELIVERY; HUMAN; IMMUNITY; INFANT DISEASE; INFECTION SENSITIVITY; MALARIA FALCIPARUM; PARASITE TRANSMISSION; PREDICTION; RISK BENEFIT ANALYSIS; SIMULATION; STOCHASTIC MODEL; SURVIVAL RATE; BIOLOGICAL MODEL; CHILD; DRUG COMBINATION; DRUG RESISTANCE; IMMUNE SYSTEM; INFANT; MALARIA; PRESCHOOL CHILD; STATISTICAL MODEL; THEORETICAL MODEL; TIME; TREATMENT OUTCOME;

ANTIMALARIALS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DRUG COMBINATIONS; DRUG RESISTANCE; HUMANS; IMMUNE SYSTEM; INFANT; MALARIA; MODELS, BIOLOGICAL; MODELS, STATISTICAL; MODELS, THEORETICAL; PYRIMETHAMINE; SULFADOXINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 50549089260     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002661     Document Type: Article

References (68)

1. IPTi Consortium (2008) www.ipti-malaria.org.
2. ter Kuile F, Steketee R (2006) Intermittent preventive treatment in infants - adjusting expectations and seeing opportunity. J Inf Dis 194: 269-72.
3. IPTi Consortium Statistical Working Group report. September 2007.
4. Schellenberg D, Cisse B, Mendendez C (2006) The IPTi Consortium: research for policy and action. Trends Parasitol 22: 296-300.
5. Smith T, Killeen GF, Maire N, Ross A, Molineaux L, et al. (2006) Mathematical modeling of the impact of malaria vaccines on the clinical epidemiology and natural history of Plasmodium falciparum malaria: Overview. Am J Trop Med Hyg 75 (Suppl 2): 1-10.
6. Hastings I, Watkins WM (2006) Tolerance is the key to understanding antimalarial drug resistance. Trends Parasitol 22: 71-77.
7. Maire N, Smith T, Ross A, Owusu-Agyei S, Dietz K, Molineaux L (2006) A model for natural immunity to asexual blood stages of Plamodium falciparum malaria in endemic areas. Am J Trop Med Hyg 75 (Suppl 2): 19-31.
8. Smith T, Ross A, Maire N, Rogier C, Trape JF, Molineaux L (2006) An epidemiologic model of the incidence of acute illness in Plasmodium falciparum malaria. Am J Trop Med Hyg 75 (Suppl 2): 56-62.
9. Ross A, Maire N, Molineaux L, Smith T (2006) An epidemiologic model of severe morbidity and mortality caused by Plasmodium falciparum. Am J Trop Med Hyg 75 (Suppl 2): 63-73.
10. Smith T, Maire N, Ross A, Penny M, Chitnis N, et al. (2008) Towards a comprehensive simulation model of malaria epidemiology and control. Parasitol; in press.
11. Maire N (2008) Using volunteer computing to simulate the epidemiology and control of malaria: malariacontrol.net. In: Distributed & Grid Computing - Science made transparent for everyone;Principles, applications and supporting communities. Rechenkraft.net. in press.
12. White N (1997) Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 41: 1413-1422.
13. Watkins WM, Mberu EK, Winstanley PA, Plowe CV (1997) The efficacy of antifolate antimalarial combinations in Africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses. Parasitol Today 13: 459-464.
14. Coulibaly D, Diallo DA, Thera M, Dicko A, Guindo A, et al. (2002) Impact of pre-season treatment on incidence of falciparum malaria and parasite density at a site for testing malaira vaccines in Bandiagara, Mali. Am J Trop Med Hyg 67: 604-10.
15. Chandramohan D, Owusu-Agyei S, Carneiro I, Awine T, Amponsa-Achiano K, et al. (2005) Cluster randomised trial of intermittent preventative treatment for malaria in infants in area of high, seasonal transmission in Ghana. BMJ 331: 727-733.
16. Cairns M, Carneiro I, Milligan P, Owusu-Agyei S, Awine T, et al. (2008) Duration of protection against malaria and anaemia provided by intermittent preventive treatment in infants in Navrongo, Ghana. PLoS ONE 3(5): e2227.
17. Collins WE, Jeffery GM (1999) A retrospective examination of the patterns of recrudescence in patients infected with Plasmodium falciparum. Am J Trop Med Hyg 61: 44-48.
18. Smith T, Maire N, Dietz K, Killeen GF, Vounatsou P, et al. (2006) Relationship between the entomologic inoculation rate and the force of infection for Plasmodium falciparum malaria. Am J Trop Med Hyg 75: 11-18.
19. Schellenberg D, Aponte J, Menendez C, Alonso P (2006) Intermittent preventive malaria treament in infants (correspondence). Lancet 366: 545-546.
20. Sutherland C, Drakeley C, Schellenberg D (2007) How is childhood development of immunity to Plasmodium falciparum enhanced by certain antimalarial interventions? Malar J 6: 161.
21. Belnoue E, Costa F, Frankenberg T, Vigário AM, Voza T, et al. (2004) Protective T cell immunity against malaria liver stage after vaccination with live sporozoites under chloroquine treatment. J Immunol 172: 2487-2495.
22. Pombo D, Lawrence G, Hirunpetcharat C, Rzepcyzk C, Bryden M, et al. (2002) Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 360: 610-617.
23. Cisse B, Sokhna C, Boulanger D, Milet J, Ba E, et al. (2006) Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomised, placebo-controlled, double-trial. Lancet 367: 659-667.
24. Maasaga JJ, Kitua A, Lemnge MM, Akida J, Malle LN, et al. (2003) Effect of intermittent treatment with amodiaquine on anaemia and malarial fevers in infants in Tanzania: a randomised placebo-controlled trial. Lancet 361: 1853-1860.
25. Desai MR, Mei JV, Kariuki SK, Wannemuehler KA, Phillips-Howard PA, et al. (2003) Randomized, controlled trial of daily icon supplementation and intermittent sulfadoxine-pyrimethamine for the treatment of mild childhood anaemia in Western Kenya. J Inf Dis 187: 658-666.
26. Dicko A, Sagara I, Sissoko M, Guindo O, Diallo A, et al. (2004) Impact of intermittent preventive treatment with sulphadoxine-pyrimethamine targeting the transmission season on the incidence of clinical malaria in children of 6 months to 10 years in Kambili, Mali. Am J Trop Med Hyg 71(suppl): abstract 18.
27. Schellenberg D, Menendez C, Kahigwa E, Aponte J, Vida J, et al. (2001) Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo- controlled trial. Lancet 357: 1471-1477.
28. Schellenberg D, Menendez C, Aponte J, Kahigwa E, Tanner M, et al. (2005) Intermittent preventative antimalarial treatment for Tanzanian infants: follow-up to age 2 years of a randomised, placebo-controlled trial. Lancet 365: 1481-1483.
29. Macete E, Aide P, Aponte J, Sanz S, Mandomando I, et al. (2006) Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican infants: a randomized, placebo-controlled trial. J Inf Dis 194: 276-85.
30. Grobusch MP, Lell B, Schwarz N, Gabor J, Dörneman J, et al. (2007) Intermittent preventive treatment in infants against malaria in Gabon - a randomized, double-blind, placebo-controlled trial. J Inf Dis 196: 1595-1602.
31. Kobbe R, Kreuzberg C, Adjei S, Thompson B, Langefeld I, et al. (2007) A randomized controlled trial of extended intermittent preventive antimalarial treatment in infants. Clin Infect Dis 45: 16-25.
32. Mockenhaupt F, Reither K, Zanger P, Roepcke F, Danquah I, et al. (2007) Intermittent preventive treatment in infants as a means of malaria control: a randomized, double-blind, placebo-controlled trial in northern Ghana. Antimicrob Agents Chemother 51: 3273-3281.
33. Smith T, Hurt N, Teuscher T, Tanner M (1995) Is fever a good sign for clinical malaria in surveys of endemic communities? Am J Trop Med Hyg 52: 306-310.
34. Chandler C, Drakeley C, Reyburn H, Carneiro I (2006) The effect of altitude on parasite density case definitions. Trop Med Int Health 11: 1178-1184.
35. Chitnis N, Steketee RW, Smith T (2008) A mathematical model for the dynamics of malaria in mosquitoes feeding on a heterogeneous host population. J Biol Dynam, in press.
36. Lines J, Armstrong-Schellenberg JR (1992) For a few parasites more: inoculum size, vector control and strain-specific immunity to malaria. Parasitol Today 8: 381-382.
37. Glynn JR, Collins WE, Jeffery GM, Bradley DJ (1995) Infecting dose and severity of malaria. Trans R Soc Trop Med Hyg 89: 281-283.
38. Boyd M (1940) The influence of sporozoite dosage in vivax malaria. Am J Trop Med 20: 279.
39. Schellenberg DM, Aponte JJ, Kahigwa EA, Mshinda H, Tanner M, et al. (2003) The incidence of clinical malaria detected by active case detection in children in Ifakara, southern Tanzania. Trans R Soc Trop Med Hyg 97: 647-654.
40. Henning L, Schellenberg D, Smith T, Henning D, Alonso P, et al. (2004) A prospective study of Plasmodium falciparum multiplicity of infection and morbidity in Tanzanian children. Trans R Soc Trop Med Hyg 98: 687-694.
41. Schellenberg D, Menendez C, Aponte J, Guinovart C, Mshinda H, et al. (2004) The changing epidemiology of malaria in Ifakara Town, southern Tanzania. Trap Med Int Health 9: 68-76.
42. Gosling R, Ghani A, Deen J, von Seidlein L, Greenwood B, Chandramohan D (2008) Can changes in malaria transmission intensity explain lack of rebound and contribute to high protective efficacy of intermittent preventive treatment for malaria in infants? Malar J 7: 54.
43. Maire N, Aponte J, Ross A, Thompson R, Alonso P, et al. (2006) Modeling a field trial of the RTS,S/ASO2A malaria vaccine. Am J Trop Med Hyg 75 (Suppl 2): 104-110.
44. Binka F, Morris SS, Ross DA, Arthur P, Aryeetey ME (1994) Patterns of malaria morbidity and mortality in children in northern Ghana. Trans R Soc Trop Med Hyg 88: 381-385.
45. Stepniewska K, Taylor W, Mayxay M, Price R, Smithuis F, et al. (2004) In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up. Antimicrob Agents Chemother 48: 4271-4280.
46. Ringwald P (2005) Susceptibility of Plasmodium falciparum to antimalarial drugs: Report on global monitoring, 1996-2004.
47. INDEPTH Network (2002) Population, Health and Survival at INDEPTH Sites. Ottawa: IDRC.
48. Kobbe R, Adjei S, Kreuzberg C, Kreuels B, Thompson B, et al. (2007) Malaria incidence and efficacy of intermittent preventive treatment in infants. Malar J 6: 163.
49. Kreuels B, Kobbe R, Adjei S, Kreuzberg C, von Rodeo C, et al. (2008) Spatial variation of malaria incidence in young children from a geographically homogenous area with high endemicity. J Inf Dis 197: 85-97.
50. Chandramohan D, Webster J, Smith L, Awine T, Owusu-Agyei S, Carneiro I (2007) Is the Expanded Programme on Immunisation the most appropriate delivery system for intermittent preventive treatment of malaria in West Africa? Trap Med Int Health 12: 743-750.
51. White N (2005) Intermittent presumptive treatment for malaria. PLoS Med 2: 28-33.
52. Maire N, Tediosi F, Ross A, Smith T (2006) Predictions of the epidemiologic impact of introducing a pre-erythrocytic vaccine into the expanded program on immunization in sub-Saharan Africa. Am J Trop Med Hyg 75 (Suppl 2): 111-118.
53. Walton GA (1947) On the control of malaria in Freetown, Sierra Leone. 1. Plasmodium falciparum and Aanopheles gambiae in relation to malaria occurring in infants. Ann Trop Med Parasitol 41: 380-407.
54. Menendez C, Schellenberg D, Macete E, Aide P, Kahigwa E, et al. (2007) Varying efficacy of intermittent preventive treatment for malaria in infants in two similar trials: public health implications. Malar J 26: 132.
55. Gatton M, Martin L, Cheng Q (2004) Evolution of resistance to sulfadoxine-pyrimethamine in Plasmodium falciparum. Antimicrob Agents Chemother 48: 2116-2123.
56. Barnes K, Little F, Smith P, Evans A, Watkins W, White N (2006) Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. Clin Pharmacol Ther 80: 582-596.
57. White N (2008) How antimalarial drug resistance affects post treatment prophylaxis. Malar J 7: 9.
58. Alexander N, Sutherland C, Roper C, Cissé B, Schellenberg D (2007) Modelling the impact of intermittent preventive treatment for malaria on selection pressure for drug resistance. Malar J 6: 9.
59. Prudhomme O'Meara W, Smith D, Mckenzie F (2006) Potential impact of intermittent preventive treatment (IPT) on spread of drug-resistant malaria. PLoS Med 3: 141.
60. Carneiro I, Smith T, Lusingu J, Malima R, Utzinger J, Drakeley C (2006) Modeling the relationship between the population prevalence of Plasmodium falciparum malaria and anemia. Am J Trop Med Hyg 75 (Suppl 2): 82-89.
61. Drakeley C, Schellenberg D, Kihonda J, Sousa CA, Arez AP, et al. (2003) An estimation of the entomological inoculation rate for Ifakara a semi-urban area in a region of intense malaria transmission in Tanzania. Trop Med Int Health 8: 767-774.
62. Appawu M, Owusu-Agyei S, Dadzie S, Asoala V, Anto F, et al. (2004) Malaria transmission dynamics at a site in northern Ghana proposed for testing malaria vaccines. Trop Med Int Health 9: 164-170.
63. Schellenberg D, Kahigwa E, Drakeley C, Malende A, Wigayi J, et al. (2002) The safety and efficacy of sulfadoxine-pyrimethamine, amodiaquine, and their combination in the treatment of uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg 67: 17-23.
64. Oduro A, Anyorigya T, Hodgson A, Ansah P, Anto F, et al. (2007) A randomized comparative study of chloroquine amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated malaria in Ghana. Trop Med Int Health 10: 279-284.
65. Abacassamo F, Enosse S, Aponte J, Gomez-Olive X, Quinto L, et al. (2004) Efficacy of chloroquine, amodiaquine, sulphadoxine-pyrimethamine and combination therapy with artesunate in Mozambican children with non-complicated malaria. Trop Med Int Health 9: 200-208.
66. Mockenhaupt F, Ehrhardt S, Dzisi S, Bousema J, Wassilew N, et al. (2005) A randomised, placebo-controlled, double-blind trial on sulfadoxine-pyrimethamine alone or in combined with artesunate or amodiaquine in uncomplicated malaria. Trop Med Int Health 10: 512-520.
67. Alloueche A, Bailey W, Barton S, Bwika J, Chimpeni P, et al. (2004) Comparison of chlorproguanil-dapsone with sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomised controlled trial. Lancet 363: 1843-1848.
68. Smith T, Charlwood JD, Kihonda J, Mwankusye S, Billingsley P, et al. (1993) Absence of seasonal variation in malaria parasitaemia in an area of intense seasonal transmission. Acta Trop 54: 55-72.